BTIG analyst Julian Harrison downgraded Prometheus (RXDX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) for $200 per share. The deal makes sense as it fills a "large void" in Merck’s pipeline, the analyst tells investors in a research note. Prometheus’ PRA023 remains in the pole positions for ulcerative colitis and Crohn’s disease, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK: